SILVER SPRING, Md. (AP) -- Specialty drugmaker United Therapeutics Corp. said Monday that it received a subpoena from federal regulators looking into the company's marketing of three drugs used to treat a form of hypertension.
Investigators requested documents on the company's Remodulin injection, Tyvaso inhalation solution and Adcirca tablets. All three drugs are used to treat pulmonary arterial hypertension, a potentially fatal condition in which patients have abnormally high blood pressure in the arteries of the lungs.
The company said the subpoena from the Office of the Inspector General of the Department of Health and Human Services reflects an investigation by the Department of Justice.
United Therapeutics said it intends to cooperate with the investigation.
United Therapeutics shares fell 31 cents to $90.66 in trading.
- Health Care Industry
- Disease & Medical Conditions
- United Therapeutics